Skip to content

Efficacy And Safety of Weekly Nab-Paclitaxel Alone as First-line Chemotherapy for Elderly(=70 years) Advanced Lung Squamous Carcinoma Patients.

Efficacy And Safety of Weekly Nab-Paclitaxel Alone as First-line Chemotherapy for Elderly(=70 years) Advanced Lung Squamous Carcinoma Patients: A Prospective Concurrent Controlled Trial.

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023062
Enrollment
Unknown
Registered
2019-05-09
Start date
2019-04-25
Completion date
Unknown
Last updated
2019-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Squamous Carcinoma

Interventions

Control group:Docetaxel or Gemcitabine

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
70 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged =70 years; 2. Pathological diagnosis of stage IV lung squamous carcinoma; 3. Never received any systematic chemotherapy treatment for lung squamous carcinoma; 4. ECOG PS = 2 scores; 5. Estimated life expectancy of at least 3 months; 6. Blood routine and ECG examinations are normal; liver funtion =2.5 x upper limit of normal range(ULN);; renal function =1.5 x upper limit of normal range(ULN); 7. Compliance with the study protocol, willingness to receive the treantments; 8. Ability to understand and willingness to sign IRB-approved informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with contraindications to chemotherapy, who cannot tolerate chemotherapy or refuse chemotherapy; (2) Patients with serious uncontrolled medical diseases, with dementia or any other mental illness that may hinder the patients understanding informed consent form or filling in the questionnaires; (3) Patients who are allergic to any therapeutic ingredient or with a history of hypersensitivity reaction; (4) Patients with =grade 2 peripheral neuropathy according to CTCAE V 4.03; (5) HBsAg (+) and HBV-DNA=1×103 IU/mL; when HBsAg (+) and HBV-DNA<1×103IU/mLthe patients can be inrolled in if the researcher permit; (6) HCV antibody (+) or HIV antibody (+); (7) Patients have received any other experimental drug treatment or participated in another interventional clinical trial within 30 days prior to the screening period; (8) Patients that the researcher consider not suitable for enrollment.

Design outcomes

Primary

MeasureTime frame
PFS;

Secondary

MeasureTime frame
ORR;OS;

Countries

China

Contacts

Public ContactMeng Rui

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

mengruivip@163.com+86 13995612493

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026